Biotech Firm SeekGene Raises ￥100M in Series A Financing

(VCBeat) Jan 8, 2021 -- SeekGene today announced closing a Series A funding round of over RMB100 million yuan, with participation from BioTrack Capital and CD Capital. SeekGene plans to use the funds for the further development and clinical application of the company's single-cell sequencing platform products, so as to advance the application of single-cell sequencing technology in drug development and accelerate the domestic commercialization of self-developed products. 

Previously, SeekGene completed the angel round financing with ZhenFund in October 2018 and the Pre-A round financing worth tens of millions of yuan with Delian Capital in October 2019.

Founded in 2015, SeekGene is a technology-driven biotechnology enterprise, focusing on the development of single-cell sorting detection technology and clinical application. The high-throughput single-cell transcriptome sequencing kit independently developed by the company has reached the world's leading level in performance. This kind of product has great features of flexibility, simplicity, economy, and accuracy, which can improve the clinical transformation and application of single-cell sequencing technology.

In 2020, SeekGene has entered rapid development. The SeekOne^® MM, a high-throughput single-cell library preparation kit, has been successfully marketed, and the product's performance has reached the leading level. The company has also initially completed the development of the SeekPair^® TCR-pMHC Pairing Platform. The company has also launched the SeekOne^® Human Single-Cell Annotation Baseline Program, which aims to build a foundation for single-cell annotations and provide an effective tool for future single-cell exploration.

Founded in 2017, BioTrack Capital is a dedicated healthcare venture capital firm focused on building and incubating innovative life science companies in China. The company focuses on innovative biotech companies, innovative MedTech companies, and innovative business models in healthcare.

CD Capital is a venture capital firm specialized in life sciences and medical technology. It is currently managing both RMB and USD funds with a total size of $600 million. The company has made over 40 investments with high growth potential and earned a reputation as a premier venture capital firm with a main focus on the Chinese healthcare industry.